DrugPatentWatch Database Preview
Drugs in Development Information for DDP-225
Email this page to a colleague
What is the drug development status for DDP-225?
DDP-225 is an investigational drug.
There have been 35 clinical trials for DDP-225.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2011.
The most common disease conditions in clinical trials are Carcinoma, Nasopharyngeal Neoplasms, and Esophageal Neoplasms. The leading clinical trial sponsors are Sun Yat-sen University, Fudan University, and Peking University.
Summary for DDP-225
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 17 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2011-02-01) |
| Vendors | 7 |
Recent Clinical Trials for DDP-225
| Title | Sponsor | Phase |
|---|---|---|
| Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study | Sun Yat-sen University | Phase 1 |
| Drugs Brain and Behavior (DDP) | University of Chicago | Early Phase 1 |
| Efficacy and Safety of ddEC-ddP for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2/Phase 3 |
Clinical Trial Summary for DDP-225
Top disease conditions for DDP-225
Top clinical trial sponsors for DDP-225
US Patents for DDP-225
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
